CJC-1295

The CJC-1295 evidence base cited here is 6 sources — 3 clinical, 2 preclinical. Its strongest evidence is human — 3 clinical studies, most recently 2009 ("Activation of the GH/IGF-1 Axis by CJC-1295 Results in Serum Protein Pro…"). Regulatory status: Not FDA-approved.

• CJC-1295 with DAC is a GHRH analog engineered for LONG action — the Drug Affinity Complex (DAC) binds albumin and stretches the half-life to roughly 6–8 days, enabling once-weekly dosing.
• The trade-off: it produces continuous GH/IGF-1 elevation rather than natural pulses, which is convenient but diverges from physiological secretion and carries a higher desensitization and side-effect profile.
• Common dose-related effects include water retention, joint pain, and carpal-tunnel-type symptoms — more frequent than with short-acting pulsatile protocols.

CJC-1295 with DAC is the long-acting counterpart to Mod GRF 1-29. The DAC modification lets a single injection keep GH and IGF-1 elevated for the better part of a week, trading the natural pulsatile pattern for convenience and sustained exposure.

It is investigational, not FDA-approved, and everything below is research context rather than medical guidance.

It shares the same modified GHRH(1-29) core as the non-DAC version (30 amino acids), with an added Drug Affinity Complex — a maleimide group that covalently binds to albumin in the bloodstream. That albumin tethering is what extends the half-life to ~6–8 days (~120 hours), versus ~30 minutes for the non-DAC form. By mass it is ~3,647 Da.

The result is a steady, prolonged GHRH-receptor signal rather than discrete pulses — the central design difference, and the source of both its convenience and its drawbacks.

Like all GHRH analogs it binds pituitary GHRH receptors to stimulate GH release. But because the DAC keeps it in circulation for days, the receptor stimulation is continuous rather than pulsatile. Sustained signaling raises baseline GH/IGF-1, but animal data show it can also blunt GH pulse amplitude over time (partial desensitization) — the physiological cost of trading pulses for steady state.

There is no approved dosing. The long half-life means weekly (not daily) administration; figures below are research context only.

• Commonly reported: ~1–2 mg subcutaneously once weekly (some split into 1 mg twice weekly)
• No daily multi-pulse schedule is needed (unlike the non-DAC form)
• Dose-dependent side effects rise above ~2 mg/week in reports
• Often discussed as 8–12 weeks on, then off, with IGF-1 returning toward baseline within 2–3 weeks of stopping

• Reconstitute with bacteriostatic water injected VERY slowly down the vial wall — DAC peptides foam easily; let it sit ~5 minutes, then roll gently (never shake).
• A slightly cloudy appearance immediately after mixing is common and should clear; a solution that stays cloudy or shows particles should be discarded.
• Store reconstituted at 2–8°C; label with date and concentration. Extremely cheap product is a red flag (DAC manufacturing is complex and costlier than non-DAC).

The continuous-elevation profile drives a higher side-effect rate than pulsatile protocols. Commonly reported: water retention, joint pain, and carpal-tunnel-type symptoms. Watch for signs of excess GH (jaw or hand/foot enlargement) with prolonged use. It is not advisable with diabetes or a cancer history, may worsen sleep apnea, and long-term use warrants IGF-1 monitoring. No human safety data establishes long-term use.

• Teichman et al. (2006) — established the long (~multi-day) half-life conferred by the DAC.
• Comparative PK, DAC vs non-DAC (human crossover): ~120-hour half-life with DAC vs ~30 minutes without; the non-DAC form preserved more physiological GH patterns.
• Long-term GH/IGF-1 axis (animal, weekly, 6 months): sustained IGF-1 elevation but reduced GH pulse amplitude (partial desensitization).
• Dose-response (human, 90 days): optimal ~1–2 mg weekly; side effects rose above 2 mg.

Not FDA-approved for any use; sold as a research chemical for laboratory use only, not intended for human consumption. GH-axis peptides may also fall under sport anti-doping prohibitions — tested athletes should verify with their governing body.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.